This site is intended for healthcare professionals
  • Home
  • /
  • News & Insights
  • /
  • News trends
  • /
  • Biosimilars
  • /
  • Clinical value beyond price alone: anti-TNF biosim...
News

Clinical value beyond price alone: anti-TNF biosimilars enable early treatment

Read time: 10 mins
Last updated:19th Oct 2021
Published:19th Oct 2021
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.

Immune-mediated inflammatory diseases (IMID) are a group of chronic conditions characterised by altered immune regulation causing chronic inflammation in targeted organs or systems.

IMIDs affect approximately 3–7% of the global population, with an estimated incidence of 80 per 105 person-years1,2.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Manova M, Savova A, Vasileva M, Terezova S, Kamusheva M, Grekova D, et al. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. Front Pharmacol. 2018;9:1070–1077.
  2. Rheumatoid Arthritis. Mayo clinic. Available at https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648. Accessed 20 July 2021.
  3. Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology. 2017;56:iv30–iv48.
  4. Kim HU, Alten R, Avedano L, Dignass A, Gomollón F,·Greveson K, et al. The Future of Biosimilars: Maximizing Benefits Across Immune‑Mediated Inflammatory Diseases. Drugs. 2020;80:99–113.
  5. Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5:e000900.
  6. EMA website. Available at: ema.europa.eu/medicines/. Accessed 20 July 2021.
  7. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1:e000057.
  8. Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, et al. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients with Rheumatoid Arthritis. Results From the Norfolk Arthritis Register. Arthritis Rheumatol. 2017;69(8):1566–1575.
  9. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017;76:1348–1356.
  10. Patel D, Shelbaya A, Cheung R, Aggarwal J, Park SH, Coindreau J. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis. Adv Ther. 2019;36:2086–2095.
  11. Müskens WD, Rongen-van Dartel SAA, van Riel PLCM, Adang EMM. Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve? J Rheumatol. 2020 Nov 1;jrheum.200565. doi: 10.3899/jrheum.200565. Online ahead of print.
  12. Smolen JS, Landewé R, Bijlsma J, Burmester G, Dougados M, Kerschmaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.
  13. ACR Health policy Statement, 2021. Available at: rheumatology.org/Portals/0/Files/ACR-Health-Policy-Statements.pdf. Accessed 20 July 2021.
  14. NICE, TA715. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. 14 July 2021. Available at: www.nice.org.uk/guidance/ta715. Accessed 20 July 2021.

Developed by EPG Health for Medthority in collaboration with Biogen who provided some of the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.